Hybrid immunity by two COVID‐19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29739 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Giovanni Almanzar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Rheumatology/Special Immunology, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, Immunity, Cellular. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bavarian State Ministry of Science and the Arts for the CoVaKo project.
Abstract (Originalsprache)
This longitudinal prospective controlled multicenter study aimed to monitor immunity generated by three exposures caused by breakthrough infections (BTI) after COVID‐19‐vaccination considering pre‐existing cell‐mediated immunity to common‐corona‐viruses (CoV) which may impact cellular reactivity against SARS‐CoV‐2. Anti‐SARS‐CoV‐2‐spike‐IgG antibodies (anti‐S‐IgG) and cellular reactivity against Spike‐(S)‐ and nucleocapsid‐(N)‐proteins were determined in fully‐vaccinated (F) individuals who either experienced BTI (F+BTI) or had booster vaccination (F+Booster) compared to partially vaccinated (P+BTI) and unvaccinated (U) from 1 to 24 weeks post PCR‐confirmed infection. High avidity anti‐S‐IgG were found in F+BTI compared to U, the latter exhibiting increased long‐lasting pro‐inflammatory cytokines to S‐stimulation. CoV was associated with higher cellular reactivity in U, whereas no association was seen in F. The study illustrates the induction of significant S‐specific cellular responses in F+BTI building‐up basic immunity by three exposures. Only U seem to benefit from pre‐existing CoV immunity but demonstrated inflammatory immune responses compared to F+BTI who immunologically benefit from enhanced humoral and cellular immunity after BTI. This study demonstrates that individuals with hybrid immunity from COVID‐19‐vaccination and BTI acquire a stable humoral and cellular immune response that is maintained for at least 6 months. Our findings corroborate recommendations by health authorities to build on basic immunity by three S‐protein exposures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Pediatric Rheumatology/Special Immunology, University Hospital Würzburg, Würzburg, Germany.
- Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
- Internal Medicine III-Gastroenterology and Infectious Diseases, University Hospital of Augsburg, Augsburg, Germany.
- Institute for Hygiene and Microbiology, Julius-Maximilian-Universität Würzburg, Würzburg, Germany.
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
- German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
ORCID-Profile: Manuel Krone
Förderung
- Bavarian State Ministry of Science and the Arts for the CoVaKo project
Zitieren
APA
Almanzar, G., Koosha, K., Vogt, T., Stein, A., Ziegler, L., Asam, C., Weps, M., Schwägerl, V., Richter, L., Hepp, N., Fuchs, A., Wagenhäuser, I., Reusch, J., Krone, M., Geldmacher, C., Protzer, U., Steininger, P., Überla, K., Wagner, R., …, & Prelog, M. (2024). Hybrid immunity by two COVID‐19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2. Journal of Medical Virology. https://doi.org/10.1002/jmv.29739
Vancouver
Almanzar G, Koosha K, Vogt T, Stein A, Ziegler L, Asam C, et al. Hybrid immunity by two COVID‐19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2. Journal of Medical Virology. 2024. doi:10.1002/jmv.29739
BibTeX
@article{Almanzar2024,
author = {Almanzar, Giovanni and Koosha, Kimia and Vogt, Tim and Stein, Astrid and Ziegler, Lars and Asam, Claudia and Weps, Manuela and Schwägerl, Valeria and Richter, Lorena and Hepp, Nicola and Fuchs, Andre and Wagenhäuser, Isabell and Reusch, Julia and Krone, Manuel and Geldmacher, Christof and Protzer, Ulrike and Steininger, Philipp and Überla, Klaus and Wagner, Ralf and Liese, Johannes and Prelog, Martina},
title = {Hybrid immunity by two COVID‐19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29739}
}
EUVIMED